| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Bendamustine |
| Brand | Levact® |
| Indication | Treatment of Chronic Lymphocytic Leukaemia (CLL) |
| Assessment Process | |
| Rapid review commissioned | 01/03/2011 |
| Rapid review completed | 21/03/2011 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 08/03/2012 |
| NCPE assessment completed | 20/11/2012 |
| NCPE assessment outcome | Reimbursement recommended |
The NCPE recommends reimbursement of bendamustine (Levact®) for patients unable to tolerate fludarabine/cyclophosphamide.